← Leaderboards
Charlene Liao
Immune-Onc Therapeutics, Inc.
$2,140,000
Attributed
$2,140,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2020–21$2M$1.5M$1M$500K$0
'20
'21
Funding mix
By agency
NIH$2,140,000 · 1
By mechanism
R44$2,140,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Acute Myeloid Leukemia Cell”
- Crystal Mackall · Children'S Hosp Of Philadelphia$10,785,733
- Eric Padron · H. Lee Moffitt Cancer Ctr & Res Inst$5,329,699
- Benjamin G Vincent · Univ Of North Carolina Chapel Hill$3,644,761
- Jeffrey Alan Magee · Washington University$3,546,780
- Amanda M Schalk · Enzyme By Design, Inc.$3,543,028
- Rolf Muller · Biofluidica, Inc$3,253,766
Research focus
Acute Myeloid Leukemia CellAcute Myelocytic LeukemiaAffectAntibodiesAntibody-Dependent Cell CytotoxicityAdverse EventAntigen-Presenting CellsAppropriate DoseBiologicalBlocking AntibodiesBone MarrowCell KillingChronic Myeloid LeukemiaChronic Myelomonocytic LeukemiaClinical DevelopmentClinical InvestigatorCombined Modality TherapyCytotoxic ChemotherapyDevelopment PlansDisease RemissionDoseDose-LimitingDrug KineticsEffector T Cell
Grant awards (2)
Non-clinical Combination Pharmacology Studies and Phase 1 Clinical Development of IO-202 in Acute Myeloid Leukemia (AML)$1,070,000
R44 · FY2021 · CA · contact PI
Non-clinical Combination Pharmacology Studies and Phase 1 Clinical Development of IO-202 in Acute Myeloid Leukemia (AML)$1,070,000
R44 · FY2020 · CA · contact PI